OBJECTIVE: To develop an algorithm for optimal use of viral load testing in patients with suspected first-line antiretroviral treatment (ART) failure. METHODS: Data from a cohort of patients on first-line ART in Cambodia were analyzed in a cross-sectional way to detect markers for treatment failure. Markers with an adjusted likelihood ratio <0.67 or >1.5 were retained to calculate a predictor score. The accuracy of a 2-step algorithm based on this score followed by targeted viral load testing was compared with World Health Organization criteria for suspected treatment failure. RESULTS: One thousand eight hundred three viral load measurements of 764 patients were available for analysis. Prior ART exposure, CD4 count below baseline, 25% and 50% drop from peak CD4 count, hemoglobin drop of > or =1 g/dL, CD4 count <100 cells per microliter after 12 months of treatment, new onset of papular pruritic eruption, and visual analog scale <95% were included in the predictor score. A score >or=2 had the best combination of sensitivity and specificity and required confirmatory viral load testing for only 9% of patients. World Health Organization criteria had a similar sensitivity but a lower specificity and required viral load testing for 24.9% of patients. CONCLUSION: An algorithm combining a predictor score with targeted viral load testing in patients with an intermediate probability of failure optimizes the use of scarce resources.
OBJECTIVE: To develop an algorithm for optimal use of viral load testing in patients with suspected first-line antiretroviral treatment (ART) failure. METHODS: Data from a cohort of patients on first-line ART in Cambodia were analyzed in a cross-sectional way to detect markers for treatment failure. Markers with an adjusted likelihood ratio <0.67 or >1.5 were retained to calculate a predictor score. The accuracy of a 2-step algorithm based on this score followed by targeted viral load testing was compared with World Health Organization criteria for suspected treatment failure. RESULTS: One thousand eight hundred three viral load measurements of 764 patients were available for analysis. Prior ART exposure, CD4 count below baseline, 25% and 50% drop from peak CD4 count, hemoglobin drop of > or =1 g/dL, CD4 count <100 cells per microliter after 12 months of treatment, new onset of papular pruritic eruption, and visual analog scale <95% were included in the predictor score. A score >or=2 had the best combination of sensitivity and specificity and required confirmatory viral load testing for only 9% of patients. World Health Organization criteria had a similar sensitivity but a lower specificity and required viral load testing for 24.9% of patients. CONCLUSION: An algorithm combining a predictor score with targeted viral load testing in patients with an intermediate probability of failure optimizes the use of scarce resources.
Authors: Michael Abouyannis; Joris Menten; Agnes Kiragga; Lutgarde Lynen; Gavin Robertson; Barbara Castelnuovo; Yukari C Manabe; Steven J Reynolds; Lesley Roberts Journal: AIDS Date: 2011-08-24 Impact factor: 4.177
Authors: Manuel Koller; Geoffrey Fatti; Benjamin H Chi; Olivia Keiser; Christopher J Hoffmann; Robin Wood; Hans Prozesky; Kathryn Stinson; Janet Giddy; Portia Mutevedzi; Matthew P Fox; Matthew Law; Andrew Boulle; Matthias Egger Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Isaac Singini; Thomas B Campbell; Laura M Smeaton; Nagalingeswaran Kumarasamy; Alberto La Rosa; Sineenart Taejareonkul; Steven A Safren; Timothy P Flanigan; James G Hakim; Michael D Hughes Journal: HIV Clin Trials Date: 2016-07-29
Authors: Maya L Petersen; Erin LeDell; Joshua Schwab; Varada Sarovar; Robert Gross; Nancy Reynolds; Jessica E Haberer; Kathy Goggin; Carol Golin; Julia Arnsten; Marc I Rosen; Robert H Remien; David Etoori; Ira B Wilson; Jane M Simoni; Judith A Erlen; Mark J van der Laan; Honghu Liu; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Andreas D Haas; Olivia Keiser; Eric Balestre; Steve Brown; Emmanuel Bissagnene; Cleophas Chimbetete; François Dabis; Mary-Ann Davies; Christopher J Hoffmann; Patrick Oyaro; Rosalind Parkes-Ratanshi; Steven J Reynolds; Izukanji Sikazwe; Kara Wools-Kaloustian; D Marcel Zannou; Gilles Wandeler; Matthias Egger Journal: Lancet HIV Date: 2015-06-16 Impact factor: 12.767
Authors: Randy G Mungwira; Titus H Divala; Osward M Nyirenda; Maxwell Kanjala; Francis Muwalo; Felix A Mkandawire; Augustine Choko; Terrie E Taylor; Jane Mallewa; Joep J van Oosterhout; Miriam K Laufer; Matthew B Laurens Journal: Trop Med Int Health Date: 2018-03-30 Impact factor: 2.622
Authors: Kimcheng Choun; Reaksmey Pe; Sopheak Thai; Natalie Lorent; Lutgarde Lynen; Johan van Griensven Journal: Bull World Health Organ Date: 2012-12-12 Impact factor: 9.408
Authors: David C Boettiger; Vonthanak Saphonn; Man Po Lee; Praphan Phanuphak; Thuy Thanh Pham; Benedict Lim Heng Sim; Nagalingeswaran Kumarasamy; Kinh Van Nguyen; Pacharee Kantipong; Adeeba Kamarulzaman; Romanee Chaiwarith; Sasisopin Kiertiburanakul; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731